Auxergen Enhances Research Capabilities with New State-of-the-Art Laboratory
Baltimore, Maryland – April 4, 2025
Auxergen announces the establishment of its new, production-capable, state-of-the-art biotech laboratory at the Institute of Marine and Environmental Technology (IMET), marking a significant step almost five years to the day since installing at the Harbor Launch Incubator at IMET on April 11, 2020.
The new facilities will enable Auxergen to isolate and purify important bio compounds and conduct in-house testing of their activity and pharmacokinetics. This includes the development of phage control products for agriculture, such as XylePhage for bacterial blight in olive trees and grape vines, and the production of Katanase™, an organic personal anti-viral bio-disinfectant.
Dr. Ting-Yu Yeh, Auxergen’s Chief Scientific Officer and Founder, emphasizes the company’s commitment to both commercial development and scientific education. “Private companies have a responsibility to conduct scientific research at the university level,” says Dr. Yeh. Auxergen is currently supervising 20 students from around the world and will host additional interns from the University of Maryland, Baltimore County, and Tuskegee University in Alabama.
This expansion will support Auxergen’s mission to develop biological solutions for major challenges, including:
- Combating Multiple Drug Resistant Organisms by developing phage therapies.
- Revolutionizing disinfection with KataNaseTM, a non-chemical, antiviral, and antibacterial bio-disinfectant.
- Advancing phage display technology for therapeutic applications, such as anti-obesity medication.
- Fighting plant diseases like Olive Quick Decline Syndrome and citrus canker.
- Engineering biologics for soil bioremediation.
About Auxergen Inc.
Auxergen Inc., headquartered in Baltimore, MD, with operations in Bari, Italy, is a leader in bacteriophages and biologic solutions for human and agricultural diseases. In its commitment to advancing public health, Auxergen leverages cutting-edge research to address emerging viral, bacterial, and fungal diseases.
Media Inquiries:
443.929.9757
info@auxergen.com
